AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Repligen Corporation
Video analysis: RGEN
All videosNo video analysis for this stock yet. Request one from our team.
News: RGEN
BioLife Solutions Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of BioLife Solutions, Inc. - BLFS
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of BioLife Solutions, Inc. (NasdaqCM: BLFS) to Repligen Corporation (NasdaqGS: RGEN). Under the terms of the proposed transaction, shareholders of BioLife will receive $11.25 in cash and 0.1442 shares of Repligen common stock for each share of BioLife that they own. KSF is seeking to determine whether t.
Repligen Corporation (RGEN) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Repligen Corporation (RGEN) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Why Is Repligen (RGEN) Up 27.7% Since Last Earnings Report?
Repligen (RGEN) reported earnings 30 days ago. What's next for the stock?
Zacks Industry Outlook Halozyme, Repligen, Iovance, Arcutis and Precigen
Halozyme, Repligen, Iovance, Arcutis and Precigen have been highlighted in this Industry Outlook article.
American Capital Management Inc. Makes New $49.26 Million Investment in Repligen Corporation $RGEN
American Capital Management Inc. acquired a new position in shares of Repligen Corporation (NASDAQ: RGEN) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 361,055 shares of the biotechnology company's stock, valued at approximately $49,262,000. Repligen comprises
5 Biotech Stocks Worth Adding to Your Portfolio Now
New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position HALO, RGEN, IOVA, ARQT and PGEN in this volatile sector.
Repligen Corporation to Present at Wells Fargo 21st Annual Healthcare Conference
WALTHAM, Mass., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will participate in the Wells Fargo 21st Annual Healthcare Conference in Boston, MA. Olivier Loeillot, President and Chief Executive Officer and Jason Garland, Chief Financial Officer, will participate in an analyst-led discussion on September 9th at 1:30 p.m. ET.
25,992 Shares in Repligen Corporation $RGEN Acquired by Bank of Nova Scotia
Bank of Nova Scotia acquired a new stake in Repligen Corporation (NASDAQ: RGEN) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 25,992 shares of the biotechnology company's stock, valued at approximately $3,547,000. Several other institutional investors have also modified their holdings
Similar companies
-
Avantor, Inc.
AVTR
·
New York Stock Exchange
Compare
-
Baxter International Inc.
BAX
·
New York Stock Exchange
Compare
-
AptarGroup, Inc.
ATR
·
New York Stock Exchange
Compare
-
Bio-Rad Laboratories, Inc.
BIO
·
New York Stock Exchange
Compare
-
DaVita Inc.
DVA
·
New York Stock Exchange
Compare
-
Charles River Laboratories International, Inc.
CRL
·
New York Stock Exchange
Compare